Brenda Porter, MD, PhD Biography
- Title:
- Associate Professor of Neurology at Stanford University Medical Center
- Position:
- Pro to the question "Should Marijuana Be a Medical Option?"
- Reasoning:
-
“The average number of anti-epileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child’s seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported 25-60% seizure reduction. Other beneficial effects included increased drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for children with treatment-resistant epilepsy.”
“Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in Pediatric Treatment-Resistant Epilepsy,” Epilepsy & Behavior, Dec. 29, 2013
- Involvement and Affiliations:
-
- Associate Professor of Neurology, Stanford University Medical Center
- Member, Bio-X
- Member, Child Health Research Institute
- Member, Stanford Neurosciences Institute
- Education:
-
- MD, Washington University School of Medicine, 1995
- PhD, Neurobiology, Washington University School of Medicine, 1995
- AB, Biochemistry, Washington University, 1987
- Other:
-
- Residency, Hospital of the University of Pennsylvania, 2000
- Residency, St. Louis Children’s Hospital, 1997
- Internship, St. Louis Children’s Hospital, 1996
- Board Certification, Clinical Neurophysiology, American Board of Psychiatry and Neurology, 2003
- Board Certification, Child Neurology, American Board of Psychiatry and Neurology, 2002
- Fellowship, The Children’s Hospital of Philadelphia, 2002